BioMark Diagnostics Inc., a leading innovator in liquid biopsy technologies for early cancer detection, announced its participation in the landmark HANSE lung cancer screening trial in Germany.
The collaboration involves leading experts Prof. Dr. Jens Vogel-Claussen from Medizinische Hochschule Hannover, Prof. Dr. Martin Reck from LungenClinic Grosshansdorf, and Dr. Sabine Bohnet from Universitätsklinikum Schleswig-Holstein. Through this strategic partnership, BioMark will serve as the core diagnostic partner for Germany’s largest and most comprehensive lung cancer screening study.
The HANSE trial, which commenced in October, aims to enroll 10,000 participants from both high-risk and general population groups. The study seeks to enhance early lung cancer detection accuracy and differentiate between benign and malignant nodules by integrating metabolomic profiling, radiomic data, and clinical parameters into a risk-based model.
BioMark has been working closely with the German clinical consortium to finalize operational logistics, including sample handling and processing workflows. The initiative is supported by the EUREKA Network Program and will leverage BioMark’s advanced laboratory facilities in Quebec City—currently advancing toward full certification and accreditation to meet the rigorous standards of this large-scale European clinical study.
“This collaboration represents a transformative milestone for BioMark,” said Rashid Ahmed Bux, CEO and President of BioMark Diagnostics. “Our recent successful capital raise has allowed us to scale our laboratory operations to effectively manage this prestigious trial. We are honored to partner with Dr. Vogel-Claussen and his exceptional team. Their scientific rigor validates our liquid biopsy technology on the international stage and establishes a strong pathway to European market commercialization.”
Prof. Dr. Jens Vogel-Claussen added, “With the integration of blood-based biomarkers in the HANSE-Study, we aim to detect early lung cancer in the asymptomatic population aged 55–79 years, which is currently not eligible for lung cancer screening with low-dose CT according to current risk-assessment criteria. Furthermore, we aim to reduce the number of benign biopsies and surgical resections of positive low-dose CT cases. If successful, the blood test from BioMark Diagnostics could significantly enhance the performance of future lung cancer screening programs.”
Successful execution of the HANSE trial is expected to generate pivotal clinical evidence supporting BioMark’s regulatory submissions and commercialization efforts across North America and Europe. This partnership marks a significant step in validating BioMark’s technology platform and reinforces the company’s position as a key global player in early cancer detection.